FREEHOLD, NJ, May 17, 2018 (GLOBE NEWSWIRE) -- MEDIFIRST SOLUTIONS, INC. (OTC: MFST) (the “Company” or “Medifirst”), a provider of innovative laser technology with its FDA 510(k) cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device, is pleased to announce that it has launched a new division to the company.
As recently announced, Concierge Concepts Rx (CCRx), a new division of Medifirst Solutions, will provide a unique niche billing service to independent pharmacies who are struggling to maintain profitability. Medifirst is pleased to announce that Walter Molokie, RPh has joined the company as CEO of CCRx. Graduate of Long Island University, his expertise is in Specialty Pharmacy and Home Infusion. His background includes: Adjunct Professor of Alternate Site Pharmacy Practice-LIU, Regional Vice-President of Operations for Kabafusion, a national provider of Specialty Pharmacy and Home Infusion, Director of Pharmacy for Option Care, a Walgreens Company, Manager of Specialty Pharmacy for Direct Script, a wholly owned division of Oxford Health Care and Founder and President of Total Home Health Care.
Commented Medifirst President Bruce J. Schoengood, “We are very excited to have Walter join Medifirst. He brings decades of experience and expertise to Medifirst and CCRx. Our Time Machine Infrared Laser is product driven which requires a purchaser to be a healthcare professional that can understand and see the benefits of our laser technology, and we believe Walter will be a great ambassador of our laser product. CCRx offers pharmacies increased revenue via business and billing solutions at no cost or expense to them.” Continued Schoengood, “This business diversification, we believe, will add great value to the company. It adds a balance of both products and services that fit very comfortably within the Company’s business strategy.”
CCRx services of pharmacy consulting and revenue stream management, utilizing over 60 years of combined Specialty Pharmacy and Infusion Therapy experience, seek to increase profits for pharmacies. Our contracting services will include: sales, patient care, operations, and navigation of the complex landscape of major medical insurance billing. The CCRx division will provide key services to undervalued clients by securing reimbursement of overlooked revenue within the ever-expanding market of the specialty pharmacy market in today's healthcare system.
Specialty drugs, often described as prescription drugs that are difficult to manufacture and require special handling or administration, have limited distribution, target a narrow group of chronic diseases, and require ongoing clinical support. We believe that CCRx has the experience and expertise in Specialty Pharmacy and Infusion Therapy that many professional do not have. Industry analysts projects the total pharmaceutical industry to exceed $483 billion in 2020, with specialty pharmaceuticals making up 44% of the revenue.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for “The Time Machine” Series Laser, received clearance from the U.S. Food and Drug Administration (“FDA”) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst’s wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information. Follow on Twitter @Medi_First and for Facebook visit Medifirst Solutions.
Forward-Looking Statements:
The statements in this press release that relate to the company’s expectations about the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.